Q-omics provides the consensus-scored RPL4P7 profile across patient tissues and cancer cell-line models. RPL4P7 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RPL4P7 is differentially expressed in 5, with the highest sampling consensus in COAD. Additionally, RPL4P7 RNA expression shows 16,401 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, COAD, and LSCC as cancer lineages where RPL4P7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL4P7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL4P7 survival associations across molecular data types. RPL4P7 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL4P7 RNA expression–survival associations across cancer types. High RPL4P7 expression shows unfavorable associations in KIRC, ACC, MESO and LIHC, but favorable associations in BLCA and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RPL4P7 RNA expression.
This table summarizes RPL4P7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL4P7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL4P7 shows lower tumor expression in BLCA and THCA and higher tumor expression in COAD, HNSC and KIRC. The COAD box plot shows higher RPL4P7 RNA expression in tumor versus normal tissue (log2 FC = +0.063, t-test p = .003).
This table shows molecular features associated with RPL4P7 in patient tissues and cancer cell lines. In patient samples, RPL4P7 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
